tetano
Editor, Senior Moderator
Access Microbiol
. 2025 Jul 7;7(7):000974.v3.
doi: 10.1099/acmi.0.000974.v3. eCollection 2025. Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants
Rachel Lau[SUP] 1 [/SUP], Chandrika Senthilkumaran[SUP] 1 [/SUP], Jeffrey Chong[SUP] 1 2 [/SUP], Freda Qi[SUP] 1 3 [/SUP], Rosmol-Stanes Pulikkottil[SUP] 1 [/SUP], Jennifer Ma[SUP] 1 [/SUP], Katherene Ogbulafor[SUP] 1 [/SUP], Larry Gabe[SUP] 1 [/SUP], Kathy Manguiat[SUP] 4 [/SUP], Alyssia Robinson[SUP] 4 [/SUP], Heidi Wood[SUP] 4 [/SUP], Angel Xinliu Li[SUP] 5 [/SUP], Mohammad Mozafarihashjin[SUP] 3 5 6 [/SUP], Aaron Campigotto[SUP] 7 [/SUP], Allison J McGeer[SUP] 3 5 8 9 [/SUP], Samira Mubareka[SUP] 8 10 [/SUP], Jonathan B Gubbay[SUP] 11 [/SUP], Julianne V Kus[SUP] 1 8 [/SUP], Shelly Bolotin[SUP] 1 8 9 [/SUP], Melissa Richard-Greenblatt[SUP] 1 7 8 [/SUP], Vanessa Tran[SUP] 1 8 [/SUP]
Affiliations
Serology assays against spike, receptor binding domain (RBD) and nucleocapsid proteins of the severe acute respiratory syndrome coronavirus 2 are essential for serosurveillance. We performed a comparison of four medium-to-high throughput commercial assays [Abbott Laboratories, Ortho Clinical Diagnostics, Meso Scale Diagnostics (MSD)], one point-of-care test (ZEKMED) and a laboratory-developed plaque reduction neutralization test using a reference panel and clinical specimens. Overall, the assays showed a high positive percent agreement of ≥85% and negative percent agreement of ≥90%, with the MSD anti-spike IgG assay having the best performance (100% in both). Notably, Abbott anti-nucleocapsid IgG, MSD anti-spike IgG and ZEKMED anti-spike RBD IgM/IgG combined assays were able to detect antibodies from individuals infected with all different variants tested - Alpha, Beta, Gamma, Delta and Omicron. The limit of detection (LOD) of the assays ranged from 9.9 to 62.0 BAU ml[SUP]-1[/SUP], with the Abbott anti-spike RBD having the lowest LOD. The COVID-19 serology assays will continue to be useful in determining seroprevalence from infection and vaccination.
Keywords: coronavirus disease 2019 (COVID-19); plaque reduction neutralization test; serology; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); variants of concern.
. 2025 Jul 7;7(7):000974.v3.
doi: 10.1099/acmi.0.000974.v3. eCollection 2025. Comparison of six COVID-19 serology assays for detection of antibodies from patients infected with ancestral and a spectrum of SARS-CoV-2 variants
Rachel Lau[SUP] 1 [/SUP], Chandrika Senthilkumaran[SUP] 1 [/SUP], Jeffrey Chong[SUP] 1 2 [/SUP], Freda Qi[SUP] 1 3 [/SUP], Rosmol-Stanes Pulikkottil[SUP] 1 [/SUP], Jennifer Ma[SUP] 1 [/SUP], Katherene Ogbulafor[SUP] 1 [/SUP], Larry Gabe[SUP] 1 [/SUP], Kathy Manguiat[SUP] 4 [/SUP], Alyssia Robinson[SUP] 4 [/SUP], Heidi Wood[SUP] 4 [/SUP], Angel Xinliu Li[SUP] 5 [/SUP], Mohammad Mozafarihashjin[SUP] 3 5 6 [/SUP], Aaron Campigotto[SUP] 7 [/SUP], Allison J McGeer[SUP] 3 5 8 9 [/SUP], Samira Mubareka[SUP] 8 10 [/SUP], Jonathan B Gubbay[SUP] 11 [/SUP], Julianne V Kus[SUP] 1 8 [/SUP], Shelly Bolotin[SUP] 1 8 9 [/SUP], Melissa Richard-Greenblatt[SUP] 1 7 8 [/SUP], Vanessa Tran[SUP] 1 8 [/SUP]
Affiliations
- PMID: 40697976
- PMCID: PMC12282051
- DOI: 10.1099/acmi.0.000974.v3
Serology assays against spike, receptor binding domain (RBD) and nucleocapsid proteins of the severe acute respiratory syndrome coronavirus 2 are essential for serosurveillance. We performed a comparison of four medium-to-high throughput commercial assays [Abbott Laboratories, Ortho Clinical Diagnostics, Meso Scale Diagnostics (MSD)], one point-of-care test (ZEKMED) and a laboratory-developed plaque reduction neutralization test using a reference panel and clinical specimens. Overall, the assays showed a high positive percent agreement of ≥85% and negative percent agreement of ≥90%, with the MSD anti-spike IgG assay having the best performance (100% in both). Notably, Abbott anti-nucleocapsid IgG, MSD anti-spike IgG and ZEKMED anti-spike RBD IgM/IgG combined assays were able to detect antibodies from individuals infected with all different variants tested - Alpha, Beta, Gamma, Delta and Omicron. The limit of detection (LOD) of the assays ranged from 9.9 to 62.0 BAU ml[SUP]-1[/SUP], with the Abbott anti-spike RBD having the lowest LOD. The COVID-19 serology assays will continue to be useful in determining seroprevalence from infection and vaccination.
Keywords: coronavirus disease 2019 (COVID-19); plaque reduction neutralization test; serology; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); variants of concern.